Primary thromboprophylaxis to prevent thrombotic events in pediatric oncology patients with a malignant mediastinal mass

Children with malignant mediastinal masses have increased thrombotic events (TE). Eligible subjects with malignant mediastinal masses between January 2000 and December 2017 were evaluated for TE, with 19 among 76 subjects receiving enoxaparin thromboprophylaxis. There were 13 TEs among 76 subjects f...

Full description

Saved in:
Bibliographic Details
Published inPediatric blood & cancer Vol. 68; no. 12; pp. e29360 - n/a
Main Authors Sarangi, Susmita N., Gaballah, Marian, Nolfi‐Donegan, Deirdre, Battaglia, Maria, Amin, Seema, Amodio, John, Acharya, Suchitra S.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.12.2021
Subjects
Anticoagulants - therapeutic use
Child
Compression
Enoxaparin - therapeutic use
Hematology
Humans
mediastinal mass
Neoplasms - complications
Neoplasms - drug therapy
Oncology
Pediatrics
prevention
prophylaxis
Statistical analysis
thrombosis
Thrombosis - epidemiology
Thrombosis - etiology
Thrombosis - prevention & control
Vena Cava, Superior
Venous Thromboembolism - drug therapy
thrombosis
prophylaxis
prevention
pediatrics
mediastinal mass
Online AccessGet full text
ISSN1545-5009
1545-5017
1545-5017
DOI10.1002/pbc.29360

Cover

More Information
Summary:Children with malignant mediastinal masses have increased thrombotic events (TE). Eligible subjects with malignant mediastinal masses between January 2000 and December 2017 were evaluated for TE, with 19 among 76 subjects receiving enoxaparin thromboprophylaxis. There were 13 TEs among 76 subjects for an incidence of 17.1%. Mediastinal compression directly led to TE in 9.2% of subjects who also had statistically significant superior vena cava compression at diagnosis. Primary thromboprophylaxis did not significantly affect TE occurrence; however, larger studies are warranted to consider strategic thromboprophylaxis guided by radiological monitoring of dynamic vascular compression to improve TE outcomes.
Bibliography:Susmita N. Sarangi, Division of Pediatric Hematology and Oncology, Medstar Georgetown University Hospital, Washington, DC, USA.
Partial data presented as an abstract at the THSNA (Thrombosis and Hemostasis Summit of North America) meeting in 2014. “Sarangi S, Nolfi‐Donegan D, Bittman M, Acharya S. Prophylactic anticoagulation to prevent thromboembolic events in pediatric oncology patients with a mediastinal mass. 11. American Journal of Hematology. 2014 May;89(6).
Present address
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1545-5009
1545-5017
1545-5017
DOI:10.1002/pbc.29360